← All Lantheus Holdings, INC filings

Lantheus Holdings, INC 8-K filings

NASDAQ
LNTH
Lantheus Holdings, INC
8-K: Lantheus Holdings Reports Record Revenue and Earnings for Full Year 2023, Provides Positive 2024 Guidance
Lantheus Holdings announced strong financial results for the fourth quarter and full year 2023, with significant increases in revenue and earnings, and provided optimistic guidance for 2024.
NASDAQ
LNTH
Lantheus Holdings, INC
8-K: Lantheus Faces Patent Infringement Lawsuit Over Generic Cancer Drug
Lantheus Holdings is being sued by Novartis for patent infringement related to its generic version of the cancer drug LUTATHERA.
NASDAQ
LNTH
Lantheus Holdings, INC
8-K: Lantheus Announces CEO Succession Plan: Brian Markison to Take Helm as Mary Anne Heino Transitions to Board Chair
Lantheus Holdings, Inc. has announced a leadership transition, with Brian Markison appointed as CEO effective March 1, 2024, and Mary Anne Heino becoming Chair of the Board.